Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1537
- Registration Number
- NCT03064841
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳West China Hospital, Chengdu, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, China
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5988
- Registration Number
- NCT03057951
- Locations
- 🇺🇸
Atlanta Heart Specialists, LLC, Tucker, Georgia, United States
🇺🇸North Shore University Hospital, Manhasset, New York, United States
🇺🇸Covigilant Research, LLC, Riverside, California, United States
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
- First Posted Date
- 2017-02-20
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3730
- Registration Number
- NCT03057977
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Integrated Heart Care, Boca Raton, Florida, United States
Cardiovascular Function in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 76
- Registration Number
- NCT03055988
- Locations
- 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇩🇪Klinische Forschung Berlin GbR, Berlin, Germany
🇩🇪Praxis Dr. med. Claus Keller, Frankfurt, Germany
Characteristics of Empagliflozin Initiators
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31908
- Registration Number
- NCT03050619
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT03047031
- Locations
- 🇮🇳
P.D. Hinduja National Hospital, Mumbai, India
🇮🇳Asthma Bhawan, Jaipur, India
🇮🇳CK Birla Hospitals, The Calcutta Medical Research Institute, Kolkata, India
Drug Utilization Study for Olodaterol
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27606
- Registration Number
- NCT03030638
- Locations
- 🇫🇷
IMS Health Information solutions, Courbevoie, France
🇳🇱Pharmo Institute, Utrecht, Netherlands
🇩🇰Aarhus Universitetshospital Skejby, Aarhus, Denmark
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42534
- Registration Number
- NCT03026556
- Locations
- 🇺🇸
Inventiv Health, Princeton, New Jersey, United States
To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: T80/A5/H12.5 FDC
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 676
- Registration Number
- NCT03021265
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan
Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT03017885
- Locations
- 🇮🇳
Action Cancer Hospital, Delhi, Delhi, India
🇮🇳Apollo Health City Hospital, Hyderabad, India
🇮🇳Chittaranjan National Cancer Institute, Kolkata, India